Fibromuscular dysplasia screening

Jump to navigation Jump to search

Fibromuscular dysplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fibromuscular dysplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiorgram

X-ray

CT

MRI

Arteriography

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Management Guidelines

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

ASA/ACCF/AHA Guideline Recommendations

Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries

Case Studies

Case #1

Fibromuscular dysplasia screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fibromuscular dysplasia screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fibromuscular dysplasia screening

CDC on Fibromuscular dysplasia screening

Fibromuscular dysplasia screening in the news

Blogs on Fibromuscular dysplasia screening

Directions to Hospitals Treating Fibromuscular dysplasia

Risk calculators and risk factors for Fibromuscular dysplasia screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Screening

  • According to the American Heart Association (AHA)/American College of Cardiology guidelines, and European consensus on the diagnosis and management of fibromuscular dysplasia among patients with HTN, screening for FMD-related RAS is recommended in the following indications:[1][2]
  • 1. Age <30 years, especially in women
  • 2. Grade 3 (_180/110 mmHg), accelerated or malignant HTN,
  • 3. Resistant HTN (blood pressure target not achieved despite triple therapy at optimal doses including a diuretic)
  • 4. Small kidney without history of uropathy
  • 5. Abdominal bruit without apparent atherosclerosis
  • 6. FMD in at least another vascular territory

References

  1. Alan T. Hirsch, Ziv J. Haskal, Norman R. Hertzer, Curtis W. Bakal, Mark A. Creager, Jonathan L. Halperin, Loren F. Hiratzka, William R. C. Murphy, Jeffrey W. Olin, Jules B. Puschett, Kenneth A. Rosenfield, David Sacks, James C. Stanley, Lloyd M. Jr Taylor, Christopher J. White, John White, Rodney A. White, Elliott M. Antman, Sidney C. Jr Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page & Barbara Riegel (2006). "ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation". Journal of the American College of Cardiology. 47 (6): 1239–1312. doi:10.1016/j.jacc.2005.10.009. PMID 16545667. Unknown parameter |month= ignored (help)
  2. Alexandre Persu, Alessandra Giavarini, Emmanuel Touze, Andrzej Januszewicz, Marc Sapoval, Michel Azizi, Xavier Barral, Xavier Jeunemaitre, Alberto Morganti, Pierre-Francois Plouin & Peter de Leeuw (2014). "European consensus on the diagnosis and management of fibromuscular dysplasia". Journal of hypertension. 32 (7): 1367–1378. doi:10.1097/HJH.0000000000000213. PMID 24842696. Unknown parameter |month= ignored (help)

Template:WH Template:WS